Abstract: Metallo-β-lactamases (MBLs) are a family of Zn(II)-dependent enzymes that can hydrolyze almost all β-lactam antibiotics. Horizontal transfer of the genes encoding MBLs among Gram-negative bacteria pathogens has led to the emergence of extensively drug-resistant pathogens, which now represent a major threat to human health. As there is not to date yet a clinically available MBL inhibitor, the discovery of new MBL inhibitors has great urgency. This review highlights the recent developments in the discovery of small-molecule MBL inhibitors.
INTRODUCTION
β-Lactam antibiotics have a broad antibacterial spectrum and play an important role in the treatment of bacterial infections. However, an increasing number of bacteria have become resistant to β-lactam antibiotics as a result of their producingβ-lactamases, including Extended-Spectrum β-Lactamases (ESBLs), the AmpCβ-lactamases, and the carbapenemaseβ-lactamases. These bacteria pose a great threat to global healthcare. Carbapenemases are β-lactamases that can hydrolyze nearly all β-lactam antibiotics including carbapenems, the last-resort antibiotics against drug-resistant Gram-negative bacteria. Carbapenemasesare members of the Ambler-class A, B, and D β-lactamasesub-families. Classes A and D are serine-β-lactamases that catalyze hydrolysis using an active-site serine, while class B β-lactamases(also called metallo-β-lactamases, MBLs)are metallo-enzymes that use one or two zinc ions for their activity [1] . MBLs are divided according to their sequence homology into three subclasses (B1, B2, and B3) [2] . Among the reported MBLs, the NDM-type MBL is identified as the most widespread MBL responsible for the emergence of Gram-negative superbugs. The NDM-type MBL hydrolyzes all of the clinically effica-*Address correspondence to these authors at the School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou 450001, China; E-mail: zzuyubin@hotmail.com and Co-Innovation Center of Henan Province for New Drug R & D and Preclinical Safety, Zhengzhou 450001, China; E-mail: changjunbiao@zzu.edu.cn + The two authors contribute equally to this work.
cious β-lactams with the exception of themonobactams. As the NDM-encoding genes are always associated with transposable elements and conjugative plasmids, this MBL is now disseminated worldwide [3] . Accordingly, the development of inhibitors of MBLs is an essential strategy for maintaining the future usefulness of existing β-lactam antibiotics. While there are effective serine-β-lactamases inhibitors such as clavulanic acid, tazobactam, sulbactam, and avibactam-all of which are widely approved in combination with appropriate β-lactam antibiotics for clinical treatment [4, 5] -there are no reports of clinically useful MBL inhibitors. Accordingly, the development of new inhibitors targeting bacterial MBLs is needed urgently.
A number of recent articles provide excellent perspectives on the role of lipidation [6, 7] , biology [8, 9] , evolution [10] [11] [12] , and protein chemistry [13] [14] [15] of the metallo-β-lactamases. Additional reviews discuss the structure [16] [17] [18] [19] , mechanism [19] [20] [21] , and history [3] of metallo-β-lactamases, and summarize the various approaches [22] , including critical analysis [23] , toward the discovery of a clinically useful MBL inhibitor (and especially, NDM-1) [24] . Various MBL inhibitors have been reported. The key structural feature of these inhibitors includethetrifluoromethyl alcohol and ketone [25] , dicarboxylic acids [26, 27] , thiols [28] , sulfates [29] , hydroxamates [30] , tetrazoles [31] , and sulfonamides [32] . This review focuses on the new inhibitors against MBLs, covering the literature from 2007 till now. The review is organized based on the chemotypes of these small-molecule inhibitors.
THE DEVELOPMENT OF NEW MBL INHIBITORS

Thiol Derivatives
Compounds with a thiol group, such as the D-and Lcaptoprildiastereomers (compounds 1 and 2, Fig. 1) , inhibited MBLs as a result of their tight interaction with zinc within the active site.The captopril diastereomers were used originally to treat hypertension clinically, and were reported as New Delhi metallo-β-lactamase-1 (NDM-1) inhibitors [33] . D-Captopril was moreeffective inhibitor thanL-captopril [34] . Rydzik et al. demonstrated that L-and D-captopril had different modes of binding, using a 19 F NMR method for monitoring conformational changes and specific ligand binding to NDM-1 [35] . D-Captopril showed certain selectivitytoward the monozinc enzymes as represented by the metallo-β-lactamase subclasses B1 and B2fromBacillus cereus (BcII) and Aeromonashydrophila (CphA) [36] . Li et al. also used NMR filtering, combined with the structure-based virtual screening approach,to identify inhibitors of the clinicallyrelevant Verona Integron-encoded MBL (VIM-2) MBL [37] . From the synthesis of a series of simplified captopril analogs, Li et al. identified the N-benzyl amide of (R)-3-mercapto-2-methylpropanoic acid 3, which showed moderate inhibition against NDM-1 (IC 50 = 1µM). Compound 4, an inhibitor used in clinical practice, also showedmoderate anti-NDM-1 activity(IC 50 =10.4µM) and low toxicity [38] . Crystallographic analyses ofthe VIM-5 metallo-β-lactamase (MBL) with isoquinoline inhibitors revealed non-zinc ion binding modes [39] . Compared with other MBL-inhibitor structures with a zinc-binding thiol,thecompounds potentiatedmeropenem activity againstclinical isolates harboring MBLs.Yusof et al. [40] recently revealed that the potency of these inhibitors could be improved by shortening the length of the mercaptoalkanoyl sidechain, as exemplified by compounds5(K i = 2.3 ± 1.5 µM) and 6 (K i = 2.9 ± 0.9 µM). When the prolinering was replaced by the pipecolic acid, the inhibitory activity was maintained (7, K i = 3.4 ± 1.3 µM) while the inhibitory activity wascompletely lost when the thiol group was substituted by a carboxylic acid.Klingler et al. developed a fluorescence-based, functional assay for β-lactamase inhibitor testing [41] and applied the assay to the evaluation of several approved drugs with sulfhydryl moieties. DLThiorphan (8) and Tiopronin (9) exhibited moderate inhibitory activitywith theIC 50 value of 1.8 and 5.9 µM for NDM-1 and imipenemase-7 (IMP-7)respectively.
Faridoon et al. [42] reported analogs of compound10 ( Fig. 1) through the fragment-based screening. Structureactivity studies of these analogs against the metallo-β-lactamase IMP-1 were undertaken. Although 1,2,4-triazole-3-thiols showed strong binding, the improvements in potency (from 1: K i ~1 mM to 4i: K i ~70 µM) were modest. Aninteresting discovery was that the optimized product 11 of acylatedthiosemicarbazides possessed moderate potencyagainst the IMP-1 MBL(K i = 11 µM). In addition, several thiol derivatives ofL-amino acids (such as compound 12) also exhibited good activity against IMP-1 MBLs [43] .
Skagseth et al. [44] replaced the carboxylate group of mercaptocarboxylic acids with bioisosteric groups like phosphonate esters, phosphonic acids, and NH-tetrazoles. Compounds 13, 14 and 15 inhibited the three MBLs (VIM-2, German imipenemase-1 (GIM-1), and NDM-1).Chang et al.
[45] constructed a new scaffold, the N-substituted carbamylmethyl mercaptoacetatethioether,which inhibited MBLs from all three subclasses, but preferentially L1 from subclass B3.
Martin et al. [46] demonstrated thatthiomandelic acid 16 and 2-mercapto-3-phenylpropionic acid 17 in combination with meropenem and cefoperazone showedthe improvementsin activity against some Gram-negative carbapenemresistant isolates, especially an imipenemase (IMP) producing strain of Klebsiella pneumoniae.
The inhibitory effects of mercaptophosphonate derivatives against the three subclasses of MBLs (B1, B2, and B3) were investigated by Lassaux et al. Compound18, bearing two chloro atoms on the phenylring,wasa broad spectrum MBL inhibitor. Compound 19, the phosphonateanalog of thiomandelic acid, displayed an inhibitory activity against B1 (K i = 1 µM), B2 (K i = 5 µM) and B3 (Ki = 0.4 µM).The study also showed that the phosphonategroup of 18 interacted with the Zn 2+ ion [47] .
Nevertheless, there are many challenges of developing thiol-based MBL inhibitors.Newapproachesare needed for the further development of thiol-based MBL inhibitors.Recently, Büttner et al. [48] found that the piperidine and piperazinesubstructure provided selectivity and an increased activity on IMP-7, which is a promising result.
Dicarboxylic Acid Derivatives
Dipicolinic Acid Derivatives
2-Picolinic acid (20, Fig. 2 ) and its derivative pyridine-2,4-dicarboxylic acid (2,4-PDCA) (21) were reported as effective inhibitors againstCphA, a subclass B2 enzyme [49] . Subsequently compound 22, derived from 2,6-dipicolinic acid (DPA), was reported to be a broad-spectrum andpotentinhibitor against NDM-1, IMP-1, and VIM-2 by usingthe fragment-based drug discovery (FBDD). This compound synergized with imipenem, thereby reducing the minimal inhibitory concentrations (measured by microdilution broth MICs) of imipenem to a susceptible range for clinical strains of Escherichia coli and Klebsiellapneumoniaestrains harboring thebla NDM-1 gene [50] . Shin et al.identified 1-hydroxypyridine-2(1H)-thione-6-carboxylic acid as a firstin-class metallo-β-lactamase inhibitor against VIM-2(K i = 13 nM, ligand efficiency = 0.99), making it a promising lead candidate for antibacterial combined therapy [51] .
Phthalic Acid Derivatives
A series of 3-substituted phthalic acid derivatives were evaluated as the IMP-1 inhibitors. These compoundsand especially the p-hydroxyphenyl derivative 23-potentiated the inhibitory activity of biapenem against Pseudomonas aeruginosaproducing IMP-1 [52] . Moreover, 3-alkyloxy and 3-amino-substituted phthalic acid derivatives (compounds 24 and 25) were identified as moderatelyactive IMP-1 inhibitors, among which 3-aminophthalic acid derivatives displayed strong combination effect with biapenem as well. The study demonstrated that the 4'-hydroxypiperidine derivative (compound 26) could inhibit IMP-1and synergize the effect of various antibiotics [53] . According to Hiraiwa et al. [27] ,3-(4-hydroxypiperidin-1-yl) phthalic acid 27was another moderately active inhibitor with an IC 50 of 2.7 µM. The crystal structure of IMP-1 incomplex with the 3-aminophthalic acid derivative suggested thatsubstitution at the 6-position of the phenylringofcompound 27 could improve potency. As a result, a series of3,6-disubstituted phthalic acid derivatives were synthesizedand then evaluated for their IMP-1 inhibitory activity and synergistic effect with the carbapenembiapenem (BIPM). The 3,6-bis-(4-hydroxypiperidin-1-yl) derivative 28 was the mosteffective IMP-1 inhibitor (IC 50 = 0.27 µM), having 10-fold higher inhibitory activity than 3-(4-hydroxypiperidin-1-yl) phthalic acid.
Succinic Acids
ME1071 (compound 29) [54] ,derived frommaleic acid, was agood MBL inhibitor andpotentiated the activity of ceftazidime andcarbapenems (especially biapenem) against MBL-producing P.aeruginosa, achieving the reduction of the MICs of carbapenemsincluding VIM-2 and IMP-1. ME1071 was later reported to have a synergistic effect against strains ofEnterobacteriaceae and Acinetobacter spp. that express the NDM-1 enzyme, despite of the fact that the synergistic effect was weaker than for bacteria with IMP and VIM metallo-enzymes due to the weaker affinity of ME1071 for NDM-1 than IMP-1 and VIM-2 [55] .
Thiophene-carboxylic Acid Derivatives
Thiophene-carboxylic acid derivatives were NDM-1 inhibitors and exertedsynergistic antibacterial activity in combination with meropenem against E. coli BL21 (DE3)/pET30a-NDM-1 [56] . Compounds 30 and 31 might be used as potential compounds to discover antibacterial agents,in spite of their high IC 50 values. As revealed by flexible dockingand quantum mechanics (QM) evaluation, the side chain of thiophene-carboxylic acid displayed weak interaction with theside chain group ofonly one amino acid residue (His189), while the active site of full-length NDM-1 was composed of two zinc ions, a water-bridge molecule, and six amino acids (His189, His120, His122, Asp124, Cys208, and His250).
Cyclic Boronates
Brem et al. [57] reported that cyclic boronates acted on both serine-and metallo-β-lactamases by mimicking the common tetrahedral intermediate. Accordingly, boronatebased inhibitors could serve as the templates for the development of broad-spectrum inhibitors. The in vitro screening of cyclic boronates demonstrated that compounds32 and 33 ( Fig. 3) were potentinhibitors ofVIM-2 and NDM-1. Compound 34 displayed moderate inhibitory activity against CphA (IC 50 = 4.4µM) and OXA-10 (IC 50 = 0.33 µM).Cahill et al. [58] recently showed that cyclic boronatesinhibited both serine-and metallo-β-lactamases. Their cyclic boronates inhibited all four classes of theβ-lactamases, as represented by the class A extended spectrum β-lactamase CTX-M-15, the class C enzymeAmpC from P. aeruginosa, and the class D OXA enzymes. TheIC 50 values ranged from low micromolar to low nanomolar.
Triazoles Inhibitors
Azolylthioacetamide
The azolylthioacetamides, and especially compound 35 (K i = 1.2µM), inhibitedthe metallo-β-lactamasesand especially forthe ImiSMBL (Fig. 4) . Structure−activity relationships indicated that the aromatic carboxyl acid attached to the triazole ring improved inhibitory activity of the inhibitors against ImiS, while an aliphatic carboxyl acid group failed to enhance the activity, indicating that the aromatic carboxylic acid-substituted azolylthioacetamide was a promising scaffold for the development ofnewinhibitors targeting the ImiS (and potentially other B2 subclass enzymes) MBLs [59] .
Within another series of triazolylthioacetamidescompound 36 (K i = 0.49 µM) and its derivatives inhibited NDM-1 with an IC 50 values of 0.15-1.90 µM, while compound 36 was inactive (even at 10 µM) against the CcrA, ImiSand L1 MBLs. Structure−activity relationship studies revealed that the activity of triazolylthioacetamides was influenced by the replacement of hydrogen on the aromatic ring by chlorine, heteroatoms, or alkyl groups while leaving the aromatic ring of the triazolylthiols unmodified [60] . Sevaille et al. [61] showed a series of active compounds mainly featured either halogen or bulky bicyclic aryl substituents, having IC 50 values in the µM range towards at least four enzymes including NDM-1, VIM-2 and IMP-1. Fig. (3) . Cyclic Boronates. Chemistry, 2018, Vol. 18, No. 00 5 A family of 4,5-disubstituted 1,2,3-triazoles were identified as selective VIM-2 inhibitors by Weide et al. through biochemical screening [62] . Their study revealed that the amino substitution on the C-4 methyl of the triazole was important to achieve the high inhibitory activity against the VIM-2MBL, and thus to potentiate the antibacterial activity of imipenem. Compound37showedgood inhibitory activity against VIM-2 with an IC 50 values of 0.07 ± 0.003µM.
Fig. (2). Dicarboxylic acid derivatives
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Natural Products
The fungal natural product Aspergillomarasmine A (known as AMA) (compound38, Fig. 5 ) was found to be a promising inhibitor of NDM-1 and VIM-2 bothin vitro and in vivo [63] . Amongthese AMA derivatives, the lead compound39exhibited a synergistic effect in combination with meropenem against K. pneumoniae (BAA-2146) harboring NDM-1. AMA analogs 40 and 41, substituted by proline showed comparable activities [64] . Isomargololone (compound 42) and Nimbolide (compound 43) [65] showed appreciable binding affinity to NDM-1.Piperine (compound 44)and Norwedelic acid (compound 45)were also reported to have better inhibitory activity than L-captoprilagainst NDM-1 [66] . Recently Bergstrom et al. [67] revealed that AMA inhibited NDM-1, VIM-2, andIMP-7 via a metal ion sequestration mechanism.AMA could remove metal ion within the active site that is required for catalyzing the hydrolysis ofβ-lactam.
Peptide Inhibitors
Arginine-containing peptides were highly potent inhibitorsagainst VIM-2 as shown by kinetic assays in combination with fluorescence spectroscopy. The length of the arginine core and the composition of the N-terminal segment of these peptides were crucial to achieveVIM-2 inhibitors with sub-micromolaraffinity [68] .
Other MBLs Inhibitors
Pyrroles and Related Heterocycles
A series of novel pyrrole and pyrrolo [2,3- (Fig. 6) showed weak inhibitory effect (K i valuesranging from approximately 10 to 30 µM) against the IMP-1 MBL from P. aeruginosa and K. pneumoniae [28] . SAR results showed that the introduction of a chloro group to compounds 49 and 50enhanced the inhibitory activity of the pyrrolopyrimidine analogs.McGeary et al.revealed that the 3-carbonitrile group, vicinal 4,5-diphenyl and N- Fig. (4) . Triazole based MBL inhibitors. Fig. (5) . Natural productsand structural analogs as MBL inhibitors.
benzyl side chains of the pyrrole were important for the inhibitory potencies of these compounds against members representing the three main subclasses of MBLs, i.e. IMP-1(representing the B1 subgroup), CphA (B2), and AIM-1 (B3) [69] . 
Hydroxamates
2,5-Substituted benzophenonehydroxamic acid 55 ( Fig.  7) was identified as a potent andselective inhibitor of FEZ-1 MBL.Subsequently, thenovelhydroxamicacid-containing compoundN-hydroxy-3-[(6-(hydroxyamino)-6-oxohexyl) oxy] benzamide56 displayed reversible, competitive inhibition with K i =0.18 ± 0.06 µM against the Bla2 MBL. This result suggested that acid-containing compounds might bepromising Bla2 inhibitors [71] .
NOTA
1,4,7-Triazacyclononane-1,4,7-triacetic acid (NOTA) (compound57)and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (compound58)restored the activities of carbapenems against three classes (VIM, IMP, and NDM)of MBL-producing bacteria at concentrations of 0.06 mg/L,a value which issuperior to the results obtained with-AMA.Cytotoxicity studies results showed NOTA and DOTA werenon-haemolytic at the applied concentration. Thus, the two compounds were potential inhibitors of MBLs [72] .
Bisthiazolidines
Both theL-and D-bisthiazolidine (BTZ) enantiomers were reported to be micromolar competitive inhibitors of two B1 sub-class MBLs (IMP-1 and NDM-1). Remarkably, BTZs and especially L-CS319 (59), potentiated β-lactam activity against MBL-producing pathogens according to the cellbased time-kill assays [73] . González MM et al.presented the bisthiazolidine (BTZ) scaffold of β-lactam substrates, which could be modified with metal-binding groups to target the MBL active site. NMR spectroscopy demonstrated that they inhibited hydrolysis of imipenem in NDM-1-producing E. coli [74] .
DNA Aptamer
Single-stranded DNAs targeting the B. cereus 5/B/6 metallo-beta-lactamase were rapid, reversible, non-competitive inhibitors screened by SELEX(Systematic Evolution of Ligands by EXpotential Enrichment). Byspecifically interfering with the actives itemetal ions of the enzyme, they acted on MBLs of both Gram-positive and Gram-negative antibiotic-resistant bacteria with K i values in the nanomolar range, such as 30 residue ssDNA (K i = 0.92 nM) and 10 residue ssDNA (K i = 0.31 nM ) [75] .
Sulfonamide
VNI-41 (compound 60) was identified as a weakinhibitionagainst NDM-1 (IC 50 = 29.6 ± 1.3 µM) by virtual screening methodologies. The sulfonamide group of VNI-41 directly interacted with Zn 2+ within the activesite, which was critical for its activity. The study supported the conclusionthatthe sulfonamide was a valid functional group for the rational design of NDM-1 inhibitors [76] .
Chromone Inhibitors
A novel reversible covalent inhibitor of the clinically relevant MBL NDM-1 (compound 61) was reported for the first time, suggesting a new way of finding potent MBLs inhibitors in spite that compound 61has to be further optimized for a therapeutic use.Electrospray ionization-mass spectrometry (ESI-MS) and single site-directed mutagenesis demonstrated that the inhibitor formed a covalent bond with Lys224 in the active site of NDM-1 [77] . Likewise, the chromone-containing compound 62 was a promising scaffold for the design of a broad-spectrum MBL inhibitor and showed high ligand efficiencies (LE) for NDM-1 with 0.39 kcal/mol per heavy atomand the LE for VIM-2 with 0.31 kcal/mol per heavy atomby using an orthogonal screening strategy combining a SPR-based assay and an enzyme inhibition assay. However, it acted less effectively on VIM-2 than NDM-1 due to a higher affinity for NDM-1 [78] .
Phenylformic Acid Derivatives
Based on the FBDD strategy, compound 63(IC 50 = 8 µM) was considered to be a new scaffold for designingpotent VIM-2inhibitors. The carboxyl group and the carbonyl group were assumed to beimportant for the activity.Furthermore, theSPR-based biosensor assay wasused to studythe kinetics of NDM-1 inhibitors [77] . This methodology may have general value for the discovery of other MBLs inhibitors.
Quinoline Inhibitors
Compounds 64 and 65 were broad-spectrum inhibitors against three clinically relevant MBLs (IMP-1, NDM-1 and VIM-2). Compound 65 interacted with the metal ion of NDM-1. Moreover, it potentiated the activity of cefoxitin on a VIM-2-producing E. colistrain in vitro [79] .
The intensity of the effort to discover effective MBL inhibitors is underscored by the diversity of publications that have occurred since the editorial acceptance of this review. These new efforts include complementary review [80, 81] experimental studies on the structure and mechanism of the MBLs [82] [83] [84] [85] [86] ; computational study of the MBL mechanism [87, 88] ; ITC as a screening method for inhibitor discovery [89] ; new inhibitor structures [90] [91] [92] [93] [94] [95] ; thiol-modified NOTA inhibitor structures [96] ; and computational screening in support of new inhibitor discovery [97] [98] [99] .
CONCLUSION
The emergence of antibiotic resistance of Gram-negative pathogens represents a major threat to human health. It is urgent to develop new antibiotic agents to fight against antibiotic resistance. Metallo-β-lactamases (MBLs) are an important class of Zn(II)-dependent enzymes that can hydrolyze almost all of β-lactams and render bacteria resistant to antibiotics in clinic. To date, there are no clinically available MBL inhibitors although a large number of MBL inhibitors have been identified. In this review, we highlight recent development of small-molecule MBL inhibitors developed in the past decade.
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